ViewRay, Inc. (NASDAQ:VRAY) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by, and welcome to the Second Quarter 2020 ViewRay Earnings Conference Call. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Ms. Michaella Gallina. Please go ahead, ma'am.
Thank you, operator. Good afternoon, everyone, and welcome to ViewRay's second quarter 2020 financial results conference call. Joining me today are Scott Drake, our President and Chief Executive Officer; and Zach Stassen, our Chief Financial Officer.
Earlier today, ViewRay issued a press release and presentation for today's call. The presentation can be viewed live on our webcast or downloaded from the Financial Events and Webinars portion of our website at www.investors.viewray.com. Today's call is being broadcast and webcast live, and a replay will be available on our website for 14 days.
Before we begin, I would like to caution listeners that comments made by management during this call may include forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties, and actual results could differ from those projected in any forward-looking statement due to numerous factors. For a description of these risks and uncertainties, please see ViewRay's annual report on Form 10-K for the fiscal year ended December 31, 2019 and its quarterly reports on Form 10-Q as updated periodically with the company's other SEC filings.
Furthermore, the content of this conference call contains time-sensitive information accurate only as of today, July 30, 2020. ViewRay undertakes no obligation to revise or otherwise update any statements to reflect events or circumstances after the date of this call.
I will now turn the call over to Scott.
Thanks, Michaella and welcome to our Q2 call. During our time together, we will first share the progress we've made over the last two years. We'll discuss our Q2 results and highlight actions taken to elongate our cash runway in light of the COVID-19 pandemic. We will clearly define our clinical, strategic and economic value propositions that set us apart in the marketplace. We will delve more deeply into how we're driving the trend toward greater utilization of complex SBRT, what we call MRIdian SMART, and our blueprint to become a first-line therapy in certain cancer types. Zach will go more deeply into our financial results, and then we look forward to answering your questions.
If you're not on the webcast, I'll be referring to slides from the presentation on our Investor Relations site. On Slide 3, our mission is to treat and prove what others can't. We anticipate that we will treat our 10,000th patient next month, a meaningful milestone. We also currently have more than 2,200 published clinical experiences and outcomes, which represent the preponderance of patient literature on MR-guided [Phonetic] radiation therapy. This compelling and growing body of data is critical to our efforts to change and improve the paradigm of care.
Turning to Slide 4. Two years ago, our team set out to build a solid foundation that would drive therapy adoption, improve cancer care